idarubicin has been researched along with Burkitt Lymphoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McKenzie, IF; Pietersz, GA; Rowland, AJ | 1 |
| Cattan, AR; Maung, ZT | 1 |
| Barbui, T; Bassan, R; Casula, P; Corneo, G; Coser, P; Fabris, P; Izzi, T; Lambertenghi-Deliliers, G; Lerede, T; Morandi, S; Pogliani, E; Rossi, G; Vespignani, M | 1 |
1 trial(s) available for idarubicin and Burkitt Lymphoma
| Article | Year |
|---|---|
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinic
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Female; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Vincristine | 1999 |
2 other study(ies) available for idarubicin and Burkitt Lymphoma
| Article | Year |
|---|---|
Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antigens, CD; Antigens, CD19; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Burkitt Lymphoma; Cell Division; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Flow Cytometry; Idarubicin; Immunotoxins; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Remission Induction; Time Factors; Tumor Cells, Cultured | 1993 |
A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines.
Topics: Animals; Antineoplastic Agents; Burkitt Lymphoma; Coloring Agents; Daunorubicin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Experimental; Male; Mice; Mice, SCID; Multiple Myeloma; Tetrazolium Salts; Toxicity Tests; Tumor Cells, Cultured | 1996 |